Premier Neurology | Greer, SC
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
OLE Inclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
746 participants in 2 patient groups
Loading...
Central trial contact
Reference Study ID Number: GN41851 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal